121 related articles for article (PubMed ID: 10319407)
21. Next-generation RNA sequencing reveals differential expression of MYCN target genes and suggests the mTOR pathway as a promising therapy target in MYCN-amplified neuroblastoma.
Schramm A; Köster J; Marschall T; Martin M; Schwermer M; Fielitz K; Büchel G; Barann M; Esser D; Rosenstiel P; Rahmann S; Eggert A; Schulte JH
Int J Cancer; 2013 Feb; 132(3):E106-15. PubMed ID: 22907398
[TBL] [Abstract][Full Text] [Related]
22. Relational mapping of MYCN and DDXI in band 2p24 and analysis of amplicon arrays in double minute chromosomes and homogeneously staining regions by use of free chromatin FISH.
Pandita A; Godbout R; Zielenska M; Thorner P; Bayani J; Squire JA
Genes Chromosomes Cancer; 1997 Nov; 20(3):243-52. PubMed ID: 9365831
[TBL] [Abstract][Full Text] [Related]
23. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
24. ID2 expression is not associated with MYCN amplification or expression in human neuroblastomas.
Wang Q; Hii G; Shusterman S; Mosse Y; Winter CL; Guo C; Zhao H; Rappaport E; Hogarty MD; Maris JM
Cancer Res; 2003 Apr; 63(7):1631-5. PubMed ID: 12670915
[TBL] [Abstract][Full Text] [Related]
25. Role of DEAD box 1 in retinoblastoma and neuroblastoma.
Godbout R; Li L; Liu RZ; Roy K
Future Oncol; 2007 Oct; 3(5):575-87. PubMed ID: 17927523
[TBL] [Abstract][Full Text] [Related]
26. Identification and chromosome mapping of the mouse homologue of the human gene (DDX6) that encodes a putative RNA helicase of the DEAD box protein family.
Akao Y; Matsuda Y
Cytogenet Cell Genet; 1996; 75(1):38-44. PubMed ID: 8995487
[TBL] [Abstract][Full Text] [Related]
27. A Drosophila melanogaster homologue of the human DEAD-box gene DDX1.
Rafti F; Scarvelis D; Lasko PF
Gene; 1996 Jun; 171(2):225-9. PubMed ID: 8666277
[TBL] [Abstract][Full Text] [Related]
28. DEAD-Box Protein RNA-Helicase DDX6 Regulates the Expression of HER2 and FGFR2 at the Post-Transcriptional Step in Gastric Cancer Cells.
Tajirika T; Tokumaru Y; Taniguchi K; Sugito N; Matsuhashi N; Futamura M; Yanagihara K; Akao Y; Yoshida K
Int J Mol Sci; 2018 Jul; 19(7):. PubMed ID: 29987267
[TBL] [Abstract][Full Text] [Related]
29. A tumour-associated DEAD-box protein, rck/p54 exhibits RNA unwinding activity toward c-myc RNAs in vitro.
Akao Y; Yoshida H; Matsumoto K; Matsui T; Hogetu K; Tanaka N; Usukura J
Genes Cells; 2003 Aug; 8(8):671-6. PubMed ID: 12875652
[TBL] [Abstract][Full Text] [Related]
30. TWIST1 is a direct transcriptional target of MYCN and MYC in neuroblastoma.
Selmi A; de Saint-Jean M; Jallas AC; Garin E; Hogarty MD; Bénard J; Puisieux A; Marabelle A; Valsesia-Wittmann S
Cancer Lett; 2015 Feb; 357(1):412-418. PubMed ID: 25475555
[TBL] [Abstract][Full Text] [Related]
31. The RNA-helicase DDX21 upregulates CEP55 expression and promotes neuroblastoma.
Putra V; Hulme AJ; Tee AE; Sun JQJ; Atmadibrata B; Ho N; Chen J; Gao J; Norris MD; Haber M; Kavallaris M; Henderson MJ; McCarroll J; Trahair T; Liu T; Liu PY
Mol Oncol; 2021 Apr; 15(4):1162-1179. PubMed ID: 33497018
[TBL] [Abstract][Full Text] [Related]
32. Disruption of cooperation between Ras and MycN in human neuroblastoma cells promotes growth arrest.
Yaari S; Jacob-Hirsch J; Amariglio N; Haklai R; Rechavi G; Kloog Y
Clin Cancer Res; 2005 Jun; 11(12):4321-30. PubMed ID: 15958613
[TBL] [Abstract][Full Text] [Related]
33. MYCN concurrence with SAHA-induced cell death in human neuroblastoma cells.
Cortés C; Kozma SC; Tauler A; Ambrosio S
Cell Oncol (Dordr); 2015 Oct; 38(5):341-52. PubMed ID: 26306783
[TBL] [Abstract][Full Text] [Related]
34. DDX6 post-transcriptionally down-regulates miR-143/145 expression through host gene NCR143/145 in cancer cells.
Iio A; Takagi T; Miki K; Naoe T; Nakayama A; Akao Y
Biochim Biophys Acta; 2013 Oct; 1829(10):1102-10. PubMed ID: 23932921
[TBL] [Abstract][Full Text] [Related]
35. MYCN amplification confers enhanced folate dependence and methotrexate sensitivity in neuroblastoma.
Lau DT; Flemming CL; Gherardi S; Perini G; Oberthuer A; Fischer M; Juraeva D; Brors B; Xue C; Norris MD; Marshall GM; Haber M; Fletcher JI; Ashton LJ
Oncotarget; 2015 Jun; 6(17):15510-23. PubMed ID: 25860940
[TBL] [Abstract][Full Text] [Related]
36. [Increased expression of the MYCN oncogene in human neuroblastoma cells and possible, new therapeutic approaches].
Schweigerer L; Fotsis T
Klin Padiatr; 1991; 203(4):319-22. PubMed ID: 1942938
[TBL] [Abstract][Full Text] [Related]
37. Non-syntenic amplification of MDM2 and MYCN in human neuroblastoma.
Corvi R; Savelyeva L; Breit S; Wenzel A; Handgretinger R; Barak J; Oren M; Amler L; Schwab M
Oncogene; 1995 Mar; 10(6):1081-6. PubMed ID: 7700632
[TBL] [Abstract][Full Text] [Related]
38. CD44H expression by human neuroblastoma cells: relation to MYCN amplification and lineage differentiation.
Gross N; Beretta C; Peruisseau G; Jackson D; Simmons D; Beck D
Cancer Res; 1994 Aug; 54(15):4238-42. PubMed ID: 7518353
[TBL] [Abstract][Full Text] [Related]
39. Ability of circular extrachromosomal DNA molecules to carry amplified MYCN proto-oncogenes in human neuroblastomas in vivo.
VanDevanter DR; Piaskowski VD; Casper JT; Douglass EC; Von Hoff DD
J Natl Cancer Inst; 1990 Dec; 82(23):1815-21. PubMed ID: 2250296
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of endothelial cell growth inhibitors by enhanced MYCN oncogene expression in human neuroblastoma cells.
Fotsis T; Breit S; Lutz W; Rössler J; Hatzi E; Schwab M; Schweigerer L
Eur J Biochem; 1999 Aug; 263(3):757-64. PubMed ID: 10469139
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
